Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-08-02 , DOI: 10.1016/s1470-2045(24)00334-6
Nicoletta Colombo ₁ , Elena Biagioli ₂ , Kenichi Harano ₃ , Francesca Galli ₂ , Emma Hudson ₄ , Yoland Antill ₅ , Chel Hun Choi ₆ , Manuela Rabaglio ₇ , Frederic Marmé ₈ , Christian Marth ₉ , Gabriella Parma ₁₀ , Lorena Fariñas-Madrid ₁₁ , Shin Nishio ₁₂ , Karen Allan ₁₃ , Yeh Chen Lee ₁₄ , Elisa Piovano ₁₅ , Beatriz Pardo ₁₆ , Satoshi Nakagawa ₁₇ , John McQueen ₁₃ , Claudio Zamagni ₁₈ , Luis Manso ₁₉ , Kazuhiro Takehara ₂₀ , Giulia Tasca ₂₁ , Annamaria Ferrero ₂₂ , Germana Tognon ₂₃ , Andrea Alberto Lissoni ₂₄ , Mariacristina Petrella ₂₅ , Maria Elena Laudani ₁₅ , Eliana Rulli ₂ , Sara Uggeri ₂ , M Pilar Barretina Ginesta ₂₆ ,

Affiliation

European Institute of Oncology IRCCS, Milan, Italy; University of Milan-Bicocca, Milan, Italy.
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Velindre Cancer Centre, Cardiff, UK.
Peninsula Health, Monash University, Melbourne, VIC, Australia.
Department of Obstetrics and Gynecology, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Medical Oncology, Inselspital, University Hospital Bern, Bern, Switzerland.
Obstetrics and Gynecology, Section Gynecologic Oncology, Universitaetsklinikum Mannheim Medizinische Fakultaet, Mannheim, Germany.
Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.
European Institute of Oncology IRCCS, Milan, Italy.
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK.
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
AOU Città della Salute e della Scienza di Torino - Presidio Sant'Anna, Torino, Italy.
Department of Medical Oncology, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Hospital 12 de Octubre, Madrid, Spain.
Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan.
UOC Oncologia 2 IRCCS Istituto Oncologico Veneto - Padova, Padova, Italy.
Academic Division Obstetrics and Gynaecology, Mauriziano Hospital, University Department of Surgical Sciences, Torino, Italy.
UO Ostetricia-Ginecologia ASST Spedali Civili, Università degli Studi-Brescia, Brescia, Italy.
UOS Oncologia Ginecologica Medica, Università degli Studi di Milano Bicocca, IRCCS San Gerardo dei Tintori - Monza, Monza, Italy.
SOD Oncologia Medica Ginecologica, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Medical Oncology, Institut Català d'Oncologia & IDIBGI, Girona, Spain.

At the time of AtTEnd trial design, standard treatment for advanced or recurrent endometrial cancer included carboplatin and paclitaxel chemotherapy. This trial assessed whether combining atezolizumab with chemotherapy might improve outcomes in this population.

中文翻译：